Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PT 00114

Next Previous
Drug Profile

PT 00114

Alternative Names: PT-00114; PT100114

Latest Information Update: 26 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protagenic Therapeutics
  • Developer Charles River Laboratories; Protagenic Therapeutics
  • Class Antidepressants; Anxiolytics; Drug withdrawal therapies; Peptides
  • Mechanism of Action Corticotropin-releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Generalised anxiety disorder; Major depressive disorder; Opioid-related disorders; Post-traumatic stress disorders
  • Phase I Mood disorders
  • No development reported Anxiety disorders; Depressive disorders; Impulse control disorders; Neurodegenerative disorders

Most Recent Events

  • 01 Aug 2025 Phase-I clinical trials in Mood disorders (In volunteers) in Germany (unspecified route) (EUCT2024-519316-13-00)
  • 28 Apr 2024 No recent reports of development identified for preclinical development in Anxiety-disorders in Finland (SC, Injection)
  • 28 Apr 2024 No recent reports of development identified for preclinical development in Depressive disorders in Finland (SC, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top